Feasibility of oral ketamine for bipolar depression: a 20-week open-label study

Open-label, single-group feasibility study of oral ketamine in adults with bipolar depression, with an 8-week treatment phase and 12-week follow-up (total 20 weeks).

Oral ketamine is administered twice weekly, titrated from 1 mg/kg to 1.5 mg/kg and up to 2 mg/kg based on MADRS score and tolerability; doses are sipped with 50 ml orange juice over 30–60 minutes under clinical supervision.